Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
作者： E Archimbaud , X Thomas , V Leblond , M Michallet , P Fenaux
关键词:
摘要: PURPOSETo confirm and extend encouraging preliminary results of timed sequential chemotherapy (TSC) in patients with previously treated acute myelogenous leukemia (AML).PATIENTS AND METHODSWe report the regimen mitoxantrone on days 1 to 3, etoposide 8 10, cytarabine 3 10 (EMA) 133 patients, a median follow-up 40 months.RESULTSSixty percent 95% confidence interval (CI) ranging from 51% 68%, achieved complete remission (CR), including 44% (CI, 32% 57%) refractory 76% 64% 86%) late first-relapse (P = .0002). Twenty-nine did not respond therapy, 11% died toxicity. Median duration neutropenia thrombocytopenia was 31 29 days, respectively. Severe nonhematologic toxicity included sepsis 54% mucositis 23%. Postinduction therapy second course EMA 27 maintenance autologous bone marrow tr...
sci-hub.se 参考文章(24)
A Heinecke, C M Sauerland, W R Martin, T Büchner, W Hiddemann, Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia. ,vol. 4, pp. 184- 188 ,(1990)
M. Labopin, B. Lowenberg, G. Meloni, P. Colombat, A. Carella, B. Simonsson, I. M. Franklin, A. Burnett, E. P. Alessandrino, N. C. Gorin, R. Willemze, V. Rizzoli, P. Coser, A. Ferrant, S. Brunet Mauri, W. Helbig, E. Polli, G. Souillet, P. Herve, M. Korbling, A. Iriondo, B. Bjorkstrand, L. F. Verdonck, Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe : further evidence of the role of marrow purging by mafosfamide Leukemia. ,vol. 5, pp. 896- 904 ,(1991)
R Champlin, RP Gale, Acute myelogenous leukemia: recent advances in therapy Blood. ,vol. 69, pp. 1551- 1562 ,(1987) , 10.1182/BLOOD.V69.6.1551.BLOODJOURNAL6961551
S Amadori, W Arcese, G Isacchi, G Meloni, M C Petti, B Monarca, A M Testi, F Mandelli, Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. Journal of Clinical Oncology. ,vol. 9, pp. 1210- 1214 ,(1991) , 10.1200/JCO.1991.9.7.1210
H M Kantarjian, M J Keating, R S Walters, K B McCredie, E J Freireich, The characteristics and outcome of patients with late relapse acute myelogenous leukemia. Journal of Clinical Oncology. ,vol. 6, pp. 232- 238 ,(1988) , 10.1200/JCO.1988.6.2.232
William P. Vaughan, Judith E. Karp, Philip J. Burke, Long chemotherapy‐free remissions after single‐cycle timed‐sequential chemotherapy for acute myelocytic leukemia Cancer. ,vol. 45, pp. 859- 865 ,(1980) , 10.1002/1097-0142(19800301)45:5<859::AID-CNCR2820450506>3.0.CO;2-Z
Dorothy L. Uhlman, Clara D. Bloomfield, David D. Hurd, Bruce A. Peterson, Prognostic factors at relapse for adults with acute myeloid leukemia American Journal of Hematology. ,vol. 33, pp. 110- 116 ,(1990) , 10.1002/AJH.2830330207
J.A. Copplestone, A.G. Prentice, Acute myeloblastic leukaemia in the elderly. Leukemia Research. ,vol. 12, pp. 617- 625 ,(1988) , 10.1016/0145-2126(88)90094-X
Paul Smits, Lia Schoots, Ben E. de Pauw, Theo de Witte, Rob S. G. Holdrinet, Jos T. P. Janssen, Clemens Haanen, Prognostic factors in adult patients with acute leukemia at first relapse. Cancer. ,vol. 59, pp. 1631- 1634 ,(1987) , 10.1002/1097-0142(19870501)59:9<1631::AID-CNCR2820590918>3.0.CO;2-6
JOHN M. BENNETT, Criteria for the Diagnosis of Acute Leukemia of Megakaryocyte Lineage (M7) Annals of Internal Medicine. ,vol. 103, pp. 460- 462 ,(1985) , 10.7326/0003-4819-103-3-460